Sanofi-Backed Windward Bio Hits $225M IPO Target; Rezera Delays Listing
By Dr. Zubair Khalid, DVM, MS, PhD ·
Windward Bio, a Swiss biotechnology company backed by Sanofi, has completed its initial public offering at the $225 million target it had set. The IPO funds will support development of two respiratory drugs that the company licensed from China.
The listing proceeds as planned, while another biotech, Rezera, has postponed its own IPO, citing “market conditions.” Windward Bio’s offering reached exactly the amount the company had aimed for.
Context
The IPO provides capital for Windward Bio to advance inhaled therapies for respiratory diseases, a major area of unmet medical need. Respiratory conditions such as asthma and chronic obstructive pulmonary disease affect hundreds of millions of patients worldwide. The deal also highlights the growing trend of Western biotechs licensing drug candidates from Chinese developers, a cross-border pipeline strategy that has become more common in recent years as Chinese biotech innovation matures.
Source: original report